Microplasmin for Children trial: Results awaited
The use of microplasmin (ocriplasmin; Jetrea, ThromboGenics) was evaluated in the Microplasmin for Children (MIC) trial for use in pediatric patients. The results are forthcoming.
B+L, Walgreens to collaborate on eye health program
Bausch + Lomb (B+L) and Walgreens will collaborate on SightSense, a new online and in-store patient education program to heighten eye health awareness.
Iridex, Peregrine enter agreement
Iridex Corp. has entered into a global distribution and supply agreement with Peregrine Surgical Ltd. to become a worldwide distributor for Peregrine labeled products, and Peregrine Surgical will become part of the Iridex supply chain.
Ophthalmic pathologist Dr. Zimmerman dies
Lorenz E. Zimmerman, MD, the founder of modern ophthalmic pathology, who spent his career studying diseases of the eye, died March 16, 2013 of complications from an infection.
Anti-VEGF treatment for ROP requires further study
Intravitreal injection of anti-VEGF agents for treatment of severe retinopathy of prematurity (ROP) requires close scrutiny and further study.
April is Women’s Eye Health and Safety Month
Prevent Blindness America has designated April as Women’s Eye Health and Safety Month.
FDA approves phenylephrine solution
The FDA has approved a new drug application for phenylephrine hydrochloride ophthalmic solution, USP 2.5% and 10% (Paragon BioTeck Inc.) to dilate the pupil.
Bausch + Lomb files for initial public offering
Bausch + Lomb has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
Mobile website educates parents on eye therapies
A new mobile website, DROPS101 Web Tools (Alcon), offers digital access to product information for moxifloxacin related to the treatment of bacterial conjunctivitis in children.
San Francisco captures eyes of ASCRS, ASOA attendees
Moscone Center at the heart of annual meeting’s ophthalmic sessions, exhibition hall
‘Telling It Like It Is!’ sums state of cataract surgery
Third annual meeting delivers on innovative educational program
How to detect artifactual clues in OCT images
Achieve more accurate findings by eliminating the effects of artifacts
Anti-VEGF for ROP may still be in its infancy
Use of laser remains standard primary therapy in most populations
Evidence does not justify CXL with LASIK
Uncertainty outweighs risks, benefits of simultaneous crosslinking to prevent postLASIK ectasia
Putting a lid on evaporative dry eye
Thermal pulsation can be effective therapy for MGD, dry eye in ophthalmologists’ practice
What do you mean, I don’t own my website?
How an initial investment of time can reap benefits in site content, design, rankings
Top medical apps of 2013
Mobile technology puts health-care data in palm of hand
Playing it safe
Risk-averse behavior creates self-defeating pattern
Bringing the ‘wow’ factor back to LASIK
How technology improvements, better communication with patients can re-invigorate the market
Drug delivery poised for revolution
Broad inclusion criteria expand femtosecond laser’s reach
Large series shows increased safety, efficiency, efficacy with laser-assisted cataract surgery
IOL centration: Location, location, location
How lens position, capsulotomy size/shape affect centration, visual outcomes
Dr. Apple’s lab endures in Heidelberg
Transition places Dr. Auffarth, ‘Apple Korps’ at core of IOL research
Femtosecond laser up to challenge of complex cases
Ability to maneuver without entering the eye a plus in some difficult cataract surgeries
MIGS drawing interest of non-glaucoma specialists
Novel procedures bring glaucoma surgery into realm of cataract, corneal subspecialists
Dry eye has new point of care
Expanded array of diagnostic platforms target identification of dry eye disease
Eye infections prompt bevacizumab recall
A Georgia compounding pharmacy has recalled 40 lots of injection syringes containing bevacizumab (Avastin, Genentech/Roche) after five patients developed intraocular infections.
TG-PRK/CXL combination benefits eyes with postLASIK ectasia
Topography-guided PRK (TG-PRK) with simultaneous collagen crosslinking (CXL) shows promise as an effective treatment for patients who are highly symptomatic because of postLASIK ectasia.
Ocriplasmin approved in EU for treatment of VMT
The European Commission has approved ocriplasmin (Jetrea, ThromboGenics) in the European Union for the treatment of vitreomacular traction (VMT).
Multispot laser system receives FDA clearance
The Vitra Multispot laser (Quantel Medical) has received a 510(k) market clearance from the FDA. It is intended to deliver a cost-effective solution to ophthalmologists dealing with epidemic levels of diabetic eye disease.
